Presentation Authors: Yoichiro Kato*, Daichi Kikuchi, Tomohiko Matuura, Renpei Kato, Mitsugu Kanehira, Ryo Takata, Jun Sugimura, Takaya Abe, Wataru Obara, Morioka, Japan
Introduction: This study is to investigate the status of therapeutic agents for dysuria and recurrence in Non-muscle invasive bladder cancer (NMIBC) two groups between non-BCG therapy and BCG therapy.
Methods: NMIBC 192 cases between June 2009 and February 2017 were participated. We divided into two groups, non-BCG group and BCG group, and compared the scores of CUETO risk and presence or absence of oral history therapeutic agents for dysuria such as, Î±-1 inhibitor, distigmine bromide, dutasteride and tadalafil. Anticholinergic agent and Î²-3 adrenoceptor agonist 3 were excluded in terms of therapeutic agents for dysuria. A case of presence agents for dysuria was defined as has being medicated before the primary recurrence.
Results: There were 101 cases in non-BCG group and 91 cases in BCG group. The number of cases in the CUETO risk classification in the non-BCG group / BCG group was 0 _ 4, 5 _ 6, 7 _ 9, 10 _ 16: 58, 26, 16, 1/30, 21, 29, 11 and the tendency of the high score in the BCG group was significant (P < 0.045 Fisher test). In terms of the recurrence rate, although there was no significant difference in the recurrence rate between the two groups with 36.6% / 23.1% in the non-BCG group / BCG group (p < 0.54 log rank test), the BCG group with higher scores in the CUETO risk classification, there was a tendency for the recurrence rate to be low. Moreover, among of the cases who had medicated history of therapeutic agents for dysuria, the recurrence rates between in the non-BCG group 28 cases and in the BCG group 30 cases were 57.1% / 23.3% respectively which was significantly lower in the BCG group (p < 0.014). On the other hand, the recurrence rate in non-BCG group 73 cases / BCG group 61 cases in non-oral cases was 28.7% / 36.1% (p < 0.38), and there was no significant difference between the two groups.
Conclusions: The CUETO risk score of both groups was higher in the BCG group; however the recurrence rate tended to be higher in the non-BCG group. Therefore we think that BCG therapy would have shown the prevention effect of recurrence rate even in our study cases. Moreover, in the cases that had medicated history of therapeutic agents for dysuria, the recurrence rate was significantly higher in the non-BCG group, however, a similar trend was not observed in the BCG group. Based on the result, though it is necessary to evaluate actual urination condition in the future, there is a possibility that earlier BCG treatment intervention would be useful for recurrence prevention for a case with a history of treatment for dysuria.